Quantitation of response to therapy in calcium urolithiasis.
The physico-chemical basis for the action of various drugs in calcium nephrolithiasis may be described in terms of changes produced in the urinary state of saturation (APR), limit of metastability (FPR), or in crystal growth. The validation of this scheme for drug action requires further correlation of objective responses to drug therapy, described in terms of urinary crystallisation, with the clinical response.
D002118:Calcium / Q000652:urine*; D003460:Crystallization; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D007475:Ion Exchange Resins / Q000627:therapeutic use; D007669:Kidney Calculi / Q000188:drug therapy*; D008274:Magnesium / Q000627:therapeutic use; D010710:Phosphates / Q000627:therapeutic use
D004164:Diphosphonates; D007475:Ion Exchange Resins; D010710:Phosphates; D006852:Hydrochlorothiazide; D008274:Magnesium; D002118:Calcium